Right now, there are 5.7 million Americans living with Alzheimer’s disease. The neurodegenerative condition drastically impacts cognition, affecting memory, coordination, and language. People with Alzheimer’s also suffer from a range of other symptoms related to dementia, including agitation, anxiety, insomnia, depression and weight problems—conditions that significantly deteriorate their quality of life.
Unfortunately, treatments for those conditions are often ineffective, and sometimes harmful. But researchers at the University of Toronto think a synthetic THC drug called nabilone could be a safer, more effective alternative.
Researchers Say Synthetic THC Can Improve Quality of Life for People With Alzheimer’s
After a successful initial trial involving 39 people with moderate to severe Alzheimer’s, University of Toronto researchers are eager to learn more about how cannabinoids can treat dementia.
The study was conducted by UT professor of psychiatry and pharmacology-toxicology Krista Lanctot. And it’s the first study ever to look at the effects of a synthetic form of THC on Alzheimer’s-related agitation.
That synthetic form of THC is called nabilone and it comes in a capsule. It’s a popular form of the cannabinoid among medical researchers, due to its consistency and how easy it is to administer. And while it’s technically a synthetic cannabinoid, it’s not the same as the synthetic street drug form of cannabis called K2 or Spice.
According to reports, nabilone presents a milder version of the calming, euphoric effects of natural cannabis. And that makes it a very effective therapy for nausea, vomiting and now, say researchers, reducing agitation in people with dementia.
“We’re excited because we think this opens a whole new door for cannabinoids as a group for treating agitation in Alzheimer’s disease,” said Professor Lanctot.